4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.64
-0.29 (-3.25%)
Mar 5, 2026, 4:00 PM EST - Market closed
4D Molecular Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Revenue | 0.12 | 0.04 | 20.72 | 3.13 | 18.04 | 13.61 | Upgrade
|
| Revenue Growth (YoY) | 605.88% | -99.82% | 562.29% | -82.65% | 32.52% | 94.85% | Upgrade
|
| Cost of Revenue | 178.08 | 141.3 | 97.1 | 80.25 | 61.36 | 53.04 | Upgrade
|
| Gross Profit | -177.96 | -141.26 | -76.37 | -77.12 | -43.32 | -39.43 | Upgrade
|
| Selling, General & Admin | 49.32 | 46.58 | 36.49 | 32.91 | 28.01 | 17.24 | Upgrade
|
| Operating Expenses | 49.32 | 46.58 | 36.49 | 32.91 | 28.01 | 17.24 | Upgrade
|
| Operating Income | -227.28 | -187.84 | -112.87 | -110.03 | -71.33 | -56.66 | Upgrade
|
| Interest & Investment Income | 21.24 | 27.05 | 12.21 | 2.57 | 0.14 | 0.15 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.04 | -0.08 | -0.18 | -0.04 | -0.12 | -0.18 | Upgrade
|
| EBT Excluding Unusual Items | -206.08 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | Upgrade
|
| Pretax Income | -209.18 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | Upgrade
|
| Net Income | -209.18 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | Upgrade
|
| Net Income to Common | -209.18 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | Upgrade
|
| Shares Outstanding (Basic) | 56 | 54 | 39 | 32 | 28 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 56 | 54 | 39 | 32 | 28 | 6 | Upgrade
|
| Shares Change (YoY) | 10.07% | 37.86% | 20.95% | 16.66% | 331.23% | 25.05% | Upgrade
|
| EPS (Basic) | -3.74 | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 | Upgrade
|
| EPS (Diluted) | -3.74 | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 | Upgrade
|
| Free Cash Flow | -185.05 | -138.37 | -78.56 | -98.22 | -78.24 | -51.91 | Upgrade
|
| Free Cash Flow Per Share | -3.31 | -2.56 | -2.01 | -3.04 | -2.82 | -8.07 | Upgrade
|
| Gross Margin | - | - | - | - | -240.17% | -289.64% | Upgrade
|
| Operating Margin | -189399.17% | -507678.38% | -544.65% | -3516.52% | -395.46% | -416.28% | Upgrade
|
| Profit Margin | -174314.17% | -434778.38% | -486.59% | -3435.41% | -395.37% | -416.49% | Upgrade
|
| Free Cash Flow Margin | -154209.17% | -373975.68% | -379.11% | -3139.05% | -433.77% | -381.35% | Upgrade
|
| EBITDA | -222.71 | -183.19 | -108.66 | -107.63 | -69.81 | -55.22 | Upgrade
|
| D&A For EBITDA | 4.57 | 4.65 | 4.2 | 2.4 | 1.52 | 1.44 | Upgrade
|
| EBIT | -227.28 | -187.84 | -112.87 | -110.03 | -71.33 | -56.66 | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 13.61 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.